Dr. Christopher A. Jimenez, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 356
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Miami, Lm Miller School of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME136278 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Hospital of Miami Miami, FL
- South Miami Hospital Miami, FL
- Doctors Hospital Coral Gables, FL
Medical groups
- Neuroscience Consultants LLP (115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 356
- Services billed
- 13,831
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 199 | 131 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 122 | 87 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 72 | 68 |
| Established patient office or other outpatient visit, 20-29 minutes | 57 | 40 |
| New patient office or other outpatient visit, 45-59 minutes | 49 | 49 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 44 | 38 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 33 | 13 |
| Nerve conduction, 11-12 studies | 30 | 30 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 26 | 25 |
| Established patient office or other outpatient visit, 40-54 minutes | 19 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 39 companies reported 219 payments worth $4,953 in total to this clinician.
| AbbVie Inc. | $757 |
|---|---|
| UCB, Inc. | $465 |
| Pfizer Inc. | $334 |
| Eisai Inc. | $331 |
| Lilly USA, LLC | $251 |
| Tg Therapeutics, Inc. | $226 |
| Mallinckrodt Hospital Products Inc. | $216 |
| Neurelis, Inc. | $211 |
| Food and Beverage | $4,888 |
|---|---|
| Education | $65.17 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Oct 23, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $47.27 |
| Janssen Pharmaceuticals, Inc Aug 29, 2025 | Education in-kind | $17.90 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $158,527 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06126224 - Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05980949 - A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.